RxDoctor Payments Data

William Brinkley, MD

Medical Oncology · Salisbury, NCNPI 1861490518

Payments from drug & device makers

$551in general payments, 2019–2025

Across 25 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$260
  • Lilly USA, LLC$78
  • Astellas Pharma US Inc$51
  • Pfizer$43
  • GSK$37
  • E.r. Squibb & Sons, L.L.C.$35
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$52695%
  • Education$255%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$551 in reported general payments places this provider in the 20th percentile of 170 medical oncology providers in North Carolina.

See all medical oncology providers in North Carolina

Medicare billing

Part B allowed, 2024
$74,182
Medicare patients
288
Services billed
1,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VenclextaVenetoclax22$246,732
GilotrifAfatinib Dimaleate11$118,376
EliquisApixaban41$28,834
XareltoRivaroxaban19$13,455
Abiraterone Acetate28$11,960
Imatinib Mesylate22$5,051
Anastrozole114$1,546
ValacyclovirValacyclovir Hcl19$1,263
Dexamethasone32$674
Letrozole47$645
Oxycodone Hcl23$509
Gabapentin33$495
Hydroxyurea42$336
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen16$301
Potassium Chloride37$202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$28,83441 claims
Johnson & JohnsonXarelto$260$13,45519 claims
Lilly USA, LLCOlanzapine$78$19920 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 170 medical oncology providers in North Carolina.

Other medical oncology in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →